Clinical trial / 2021
Once-weekly semaglutide (2.4 mg) plus lifestyle intervention led to a 14.9% mean weight loss in adults with overweight or obesity.
In a double-blind trial, 1961 adults with overweight or obesity without diabetes were randomly assigned (2:1) to 68 weeks of once-weekly subcutaneous semaglutide (2.4 mg) or placebo, both combined with lifestyle intervention. Mean body weight change was -14.9% with semaglutide compared to -2.4% with placebo (difference -12.4 percentage points; P<0.001), representing a -15.3 kg vs. -2.6 kg change. Significantly more semaglutide participants achieved weight reductions of ≥5% (86.4% vs. 31.5%), ≥10% (69.1% vs. 12.0%), and ≥15% (50.5% vs. 4.9%). Transient, mild-to-moderate nausea and diarrhea were the most common adverse events, with 4.5% of semaglutide participants discontinuing treatment due to gastrointestinal events versus 0.8% with placebo.
- Study type
- Double-blind randomized controlled trial
- Who was studied
- 1961 adults with overweight or obesity without diabetes
- What was measured
- Percentage change in body weight and weight reduction of at least 5% at week 68
THE PAPER
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF, STEP 1 Study Group. N Engl J Med, 2021.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.